Several Zika virus (ZIKV) vaccine candidates have recently been described which use inactivated whole virus, DNA or RNA that express the virus’ Envelope (E) glycoprotein as the antigen. These were successful in stimulating production of virus-targeted antibodies that protected animals against ZIKV challenges, but their use potentially will predispose vaccinated individuals to infection by the related Dengue virus (DENV).
Download count: 0
Details
- Yang, Ming (Contributor)
- Lai, Huafang (Contributor)
- Sun, Haiyan (Contributor)
- Chen, Qiang (Contributor)
- Immunotherapy, Vaccines and Virotherapy (Contributor)
- Biodesign Institute (Contributor)
- 2017-08-09
- Digital object identifier: 10.1038/s41598-017-08247-9
- Identifier TypeInternational standard serial numberIdentifier Value2045-2322
- The final version of this article, as published in Scientific Reports, can be viewed online at: https://www.nature.com/articles/s41598-017-08247-9, opens in a new window
Citation and reuse
Cite this item
This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.
Yang, M., Lai, H., Sun, H., & Chen, Q. (2017). Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice. Scientific Reports, 7(1). doi:10.1038/s41598-017-08247-9